Compounds > busulfan
Page last updated: 2024-10-24

busulfan and Diffuse Lymphocytic Lymphoma, Poorly-Differentiated

busulfan has been researched along with Diffuse Lymphocytic Lymphoma, Poorly-Differentiated in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Stewart, DA1
Duan, Q1
Carlson, L1
Russell, JA1
Bahlis, NJ1
Duggan, P1
Hasegawa, W1
Voralia, M1
Grigg, AP2
Bashford, J1
Seymour, JF2
Shuttleworth, P1
Norris, D1
Hertzberg, M1
Gill, D1
Waugh, M1
Saal, R1
Marlton, P1
Ritchie, DS1
Roberts, AW1
Hoyt, R1
Thompson, S1
Szer, J1
Prince, HM1
Rodriguez, R1
Nademanee, A1
Ruel, N1
Smith, E1
Krishnan, A1
Popplewell, L1
Zain, J1
Patane, K1
Kogut, N1
Nakamura, R1
Sarkodee-Adoo, C1
Forman, SJ1
Ogura, M1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
High Dose Chemotherapy and Autologous or Allogeneic Blood Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma[NCT00144092]Phase 260 participants (Anticipated)Interventional2001-05-31Completed
Safety and Efficacy of Ibritumomab Tiuxetan (Zevalin®) in Association With a Fludarabine Based Reduced Conditioning Regimen and Allogenic Stem Cell Support in Chemo-sensitive Relapsed CD20 Positive Aggressive Non-Hodgkin's Lymphoma Patients.[NCT00607854]Phase 231 participants (Actual)Interventional2008-02-29Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for busulfan and Diffuse Lymphocytic Lymphoma, Poorly-Differentiated

ArticleYear
[Mantle cell lymphoma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2001, Volume: 42, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy

2001

Trials

3 trials available for busulfan and Diffuse Lymphocytic Lymphoma, Poorly-Differentiated

ArticleYear
A prospective phase II study of RICE re-induction, then high-dose fludarabine and busulfan, followed by autologous or allogeneic blood stem cell transplantation for indolent b-cell lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols;

2011
Autografting followed by rituximab for chemosensitive mantle cell lymphoma: a pilot study and literature review.
    Leukemia & lymphoma, 2005, Volume: 46, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agent

2005
The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.
    Annals of hematology, 2007, Volume: 86, Issue:2

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo

2007

Other Studies

1 other study available for busulfan and Diffuse Lymphocytic Lymphoma, Poorly-Differentiated

ArticleYear
Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:12

    Topics: Adolescent; Adult; Aged; Busulfan; Cause of Death; Cohort Studies; Cyclophosphamide; Disease-Free Su

2006